[Subependymal giant cell astrocytoma associated with tuberous sclerosis complex -  pharmacological treatment using...

Area of Science:

• Neuroscience
• Genetics
• Oncology

Background:

• Tuberous sclerosis complex (TSC) is a genetic disorder caused by TSC1 or TSC2 gene mutations.
• This condition leads to the abnormal activation of the mTORC1 pathway.
• Pathogenic mTORC1 activation results in subependymal giant cell astrocytomas (SEGAs), a type of low-grade brain tumor.

Purpose of the Study:

• To review current knowledge on the pharmacological treatment of SEGAs in TSC patients.
• To highlight the potential of mTOR inhibitors in managing TSC-associated brain tumors.

Main Methods:

• Literature review of current research on TSC and SEGA treatment.
• Analysis of the role of the mTORC1 pathway in SEGA development.
• Evaluation of mTOR inhibitors as a therapeutic strategy.

Main Results:

• mTORC1 pathway dysregulation is a key factor in SEGA development.
• mTOR inhibitors demonstrate potential in reducing SEGA volume.
• Pharmacological intervention offers a promising avenue for managing these tumors.

Conclusions:

• Targeting the mTORC1 pathway with inhibitors is a viable treatment strategy for SEGAs.
• Early therapeutic intervention and long-term follow-up are crucial for improving outcomes in TSC patients.
• Pharmacological treatment can lead to reduced mortality, morbidity, and improved quality of life.